All Stories

  1. TIMELY: Providing In-Time and Intelligent Support for Cardiovascular Rehabilitation with ’Patients and Practitioners in the Loop’ Interaction
  2. A single session of EMS training induces long-lasting changes in circulating muscle but not cardiovascular miRNA levels - A randomized crossover study
  3. Prognostic and therapeutic potential of microRNAs for fracture healing processes and non‐union fractures: A systematic review
  4. Corrigendum: Health benefits of probiotics in sport and exercise—Non-existent or a matter of heterogeneity? A systematic review
  5. Defining patients needs and expectations for eHealth-based cardiac rehabilitation in Germany and Spain: living lab data from the TIMELY study
  6. Patient-centered cardiac rehabilitation by AI-powered lifestyle intervention – the timely approach
  7. Patient-centered lifestyle intervention using artificial intelligence methodologies: The TIMELY project for cardiac rehabilitation
  8. Therapeutic Potential of Electromyostimulation (EMS) in Critically Ill Patients—A Systematic Review
  9. Health Benefits of Probiotics in Sport and Exercise - Non-existent or a Matter of Heterogeneity? A Systematic Review
  10. Regulation of antiatherogenic mir-126 by physical exercise
  11. Longitudinal choriocapillaris changes in the presence of reticular pseudodrusen
  12. Paracentral acute middle maculopathy following high-intensity interval training
  13. Four weeks of electromyostimulation improves muscle function and strength in sarcopenic patients: a three‐arm parallel randomized trial
  14. Sex-specific differences and long-term outcome of patients with coronary artery disease and chronic kidney disease: the Coronary Artery Disease and Renal Failure (CAD-REF) Registry
  15. Differential effects of high-intensity interval training (HIIT) on choriocapillaris perfusion in healthy adults and patients with type 1 diabetes mellitus (T1DM)
  16. Effect of high-intensity interval training in patients with type 1 diabetes on physical fitness and retinal microvascular perfusion determined by optical coherence tomography angiography
  17. Four weeks of high-intensity interval training (HIIT) improve the cardiometabolic risk profile of overweight patients with type 1 diabetes mellitus (T1DM)
  18. Yo-Yo Intermittent Recovery Level 1 Test for Estimation of Peak Oxygen Uptake: Use Without Restriction?
  19. Sex Differences in High-Intensity Interval Training–Are HIIT Protocols Interchangeable Between Females and Males?
  20. Progressive high-intensity interval training (HIIT) is not superior to unmodified non-progressive HIIT in an uncontrolled setting
  21. Correlation analysis of physical fitness and retinal microvasculature by OCT angiography in healthy adults
  22. Soluble adenylyl cyclase (sAC) regulates calcium signaling in the vascular endothelium
  23. Neutralising anti‐drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity
  24. Normative Yo-Yo Intermittent Recovery Level 1 and Yo-Yo Intermittent Endurance Level 1 test values of boys aged 9–16 years
  25. A three-step approach identifies novel shear stress-sensitive endothelial microRNAs involved in vasculoprotective effects of high-intensity interval training (HIIT)
  26. Rare non-coding Desmoglein-2 variant contributes to Arrhythmogenic right ventricular cardiomyopathy
  27. Effects of high-intensity interval training on microvascular glycocalyx and associated microRNAs
  28. Optische Kohärenztomographie-Angiographie als zukünftiges Diagnostikum in der Sportmedizin?
  29. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy
  30. Genome-wide association study suggests impact of chromosome 10 rs139401390 on kidney function in patients with coronary artery disease
  31. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease
  32. Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
  33. P3819Rare non-coding desmoglein-2 variant contributes to arrhythmogenic right ventricular cardiomyopathy
  34. Circulating non-coding RNAs as functional markers to monitor and control physical exercise for the prevention of cardiovascular disease
  35. Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure
  36. The Yo-Yo Intermittent Tests: A Systematic Review and Structured Compendium of Test Results
  37. Effects of high-intensity interval training on optic nerve head and macular perfusion using optical coherence tomography angiography in healthy adults
  38. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion
  39. Circulating microRNAs as functional biomarkers in cardioprotective exercise – The SPORTIVA study
  40. HIIT effects on optic nerve head and macular perfusion by optical coherence tomography angiography
  41. Longer Work/Rest Intervals During High-Intensity Interval Training (HIIT) Lead to Elevated Levels of miR-222 and miR-29c
  42. Comment on “Epigenetics and cardiovascular regenerative medicine in the elderly”
  43. ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRA
  44. Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma
  45. Two-year outcome and risk factors for mortality in patients with coronary artery disease and renal failure: The prospective, observational CAD-REF Registry
  46. Yo-Yo IR1 vs. incremental continuous running test for prediction of 3000-m performance
  47. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease
  48. Dose-Response of High-Intensity Training (HIT) on Atheroprotective miRNA-126 Levels
  49. Salt-induced Na+/K+-ATPase-α/β expression involves soluble adenylyl cyclase in endothelial cells
  50. Uric acid and essential hypertension
  51. Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease
  52. Physical Exercise in Patients with Fabry Disease – a Pilot Study
  53. Functional Promoter Variant in Desmocollin-2 Contributes to Arrhythmogenic Right Ventricular Cardiomyopathy
  54. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
  55. Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry)
  56. Differential response to endothelial epithelial sodium channel inhibition ex vivo correlates with arterial stiffness in humans
  57. PP.28.12
  58. Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
  59. Thromboembolic events in Fabry disease and the impact of factor V Leiden
  60. Aldosterone signaling and soluble adenylyl cyclase—A nexus for the kidney and vascular endothelium
  61. Salt controls endothelial and vascular phenotype
  62. Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A-10T genotype
  63. Identification of Genetic Markers for Treatment Success in Heart Failure Patients: Insight From Cardiac Resynchronization Therapy
  64. Soluble Adenylyl Cyclase in Vascular EndotheliumNovelty and Significance
  65. Increased monocyte adhesion by endothelial expression of VCAM-1 missense variation in vitro
  66. Tissue-specific differences in the regulation of KIBRA gene expression involve transcription factor TCF7L2 and a complex alternative promoter system
  67. Interindividual Transcriptional Regulation of the Human biglycan Gene Involves Three Common Molecular Haplotypes
  68. Multifocal White Matter Lesions Associated with the D313Y Mutation of the α-Galactosidase A Gene
  69. Genetic Variants of the Renin-Angiotensin-Aldosterone System and Reverse Remodeling After Cardiac Resynchronization Therapy
  70. Association of left ventricular mass with the AGTR1 A1166C polymorphism
  71. Are Retinal Microvascular Phenotypes Associated With the 1675G/A Polymorphism in the Angiotensin II Type-2 Receptor Gene?
  72. Knowledge extraction in a population suffering from heart failure
  73. P422 PROFILING OF BIGLYCAN MOLECULAR PROMOTER HAPLOTYPES
  74. Identification and Functional Analyses of Molecular Haplotypes of the Human Osteoprotegerin Gene Promoter
  75. Molecular investigation of the functional relevance of missense variants of ICAM-1